ANGLE plc Share Price

Equities

AGL

GB0034330679

Advanced Medical Equipment & Technology

Market Closed - London S.E. 16:35:00 17/06/2024 BST 5-day change 1st Jan Change
13.75 GBX -1.79% Intraday chart for ANGLE plc -6.78% +17.02%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site

Financials

Sales 2023 2.19M 2.77M 219M Sales 2024 * 8.03M 10.17M 803M Capitalization 44.66M 56.57M 4.47B
Net income 2023 -20M -25.34M -2B Net income 2024 * -15M -19M -1.5B EV / Sales 2023 14 x
Net cash position 2023 * 12.56M 15.92M 1.26B Net Debt 2024 * 1M 1.27M 100M EV / Sales 2024 * 5.69 x
P/E ratio 2023
-1.52 x
P/E ratio 2024 *
-2.33 x
Employees -
Yield 2023 *
-
Yield 2024 *
-
Free-Float 91.23%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on ANGLE plc

1 day-0.60%
1 week-5.65%
Current month-25.78%
1 month-32.12%
3 months-2.34%
6 months+25.37%
Current year+18.43%
More quotes
1 week
13.60
Extreme 13.6
15.50
1 month
13.60
Extreme 13.6
21.28
Current year
11.26
Extreme 11.26
37.40
1 year
9.07
Extreme 9.0667
37.40
3 years
9.07
Extreme 9.0667
163.75
5 years
9.07
Extreme 9.0667
163.75
10 years
9.07
Extreme 9.0667
163.75
More quotes
Managers TitleAgeSince
Founder 63 31/03/94
Director of Finance/CFO - 31/12/94
Chief Tech/Sci/R&D Officer - 04/06/23
Members of the board TitleAgeSince
Director of Finance/CFO - 31/12/94
Founder 63 31/03/94
Director/Board Member 80 06/01/13
More insiders
Date Price Change Volume
17/06/24 13.75 -1.79% 1 000 902
14/06/24 14 -1.75% 1,757,444
13/06/24 14.25 -1.72% 2,014,792
12/06/24 14.5 -1.69% 2,169,029
11/06/24 14.75 0.00% 1,552,190

Delayed Quote London S.E., June 17, 2024 at 10:22 am

More quotes
ANGLE plc is a United Kingdom-based liquid biopsy company with circulating tumor cell (CTC) solutions for use in research, drug development and clinical oncology using a simple blood sample. Its circulating tumor cell (CTC) harvesting technology known as the Parsortix PC1 System enables complete downstream analysis of the sample, including whole cell imaging and proteomic analysis and full genomic and transcriptomic molecular analysis. The Parsortix PC1 system is a medical device for the capture and harvest of intact CTCs from metastatic breast cancer (MBC) patient blood for user-validated analysis. Its commercial businesses focus on diagnostic products and clinical services. Its diagnostic products include the Parsortix system and associated consumables. Its services include custom made assay development and clinical trial testing for pharma. The Parsortix technology uses a microfluidic technology in the form of a single use cassette to capture and then harvest CTCs from whole blood.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.14 GBP
Average target price
0.685 GBP
Spread / Average Target
+389.29%
Consensus
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW